IL6R and familial pancreatic carcinoma: Blocking IL6 signaling was shown capable of rewiring the chemotherapeutic resistance of pancreatic cancers in vivo,175 with a clinical trial involving 140 advanced pancreatic cancer patients being launched to examine the efficacy of tocilizumab (an IL6R inhibitor) in improving the chemotherapeutic outcome (NCT02767557).